Differential activation of valvulogenic, chondrogenic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 3, 2012, Pages 689-700

  Cheek, Jonathan D ^a   Wirrig, Elaine E ^a   Alfieri, Christina M ^a   James, Jeanne F ^a   Yutzey, Katherine E ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Aortic valve disease; Calcification; Extracellular matrix; Mouse models of human disease; Valvular interstitial cells

Indexed keywords

ASPORIN; COLLAGEN TYPE 10; COLLAGEN TYPE 2; COLLAGENASE 3; KLOTHO PROTEIN; OSTEOPONTIN; PROTEOGLYCAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE DISEASE; ARTICLE; ASPORIN GENE; BONE DEVELOPMENT; CALCIFIC AORTA VALVE DISEASE; CHONDROGENESIS; COL10A1 GENE; COL1A2 GENE; COL2A1 GENE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC MARKER; HAPLN1 GENE; HEART DEVELOPMENT; INFLAMMATION; KLOTHO GENE; MMP13 GENE; MOUSE; MYXOMATOUS AORTA VALVE DISEASE; NONHUMAN; OSTEOPONTIN GENE; PERIOSTIN GENE; PHENOTYPE; PREMATURE AGING; PRIORITY JOURNAL; RUNX2 GENE; SOX9 GENE; TWIST1 GENE;

ANIMALS; AORTIC VALVE; CALCINOSIS; CELL ADHESION MOLECULES; CELL PROLIFERATION; CHONDROGENESIS; CONNECTIVE TISSUE CELLS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; GLUCURONIDASE; HEART VALVE DISEASES; HUMANS; MICE; MICE, KNOCKOUT; OSTEOGENESIS; OSTEOGENESIS IMPERFECTA; PROTEIN TRANSPORT; PROTEOGLYCANS; SIGNAL TRANSDUCTION;

MURINAE; MUS;

EID: 84857628377     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.12.013     Document Type: Article

References (59)

1. Thom T., Haase N., Rosamond W., Howard V.J., Rumsfeld J., Manolio T., et al. Heart disease and stroke statistics-2006 update. A report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2006, 113:e85-e151.
2. Roberts W.C., Ko J.M. Frequency by decades of unicuspid, bicuspid and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005, 111:920-925.
3. Freeman R.V., Otto C.M. Spectrum of calcific aortic valve disease: pathogenesis, disease progression and treatment strategies. Circulation 2005, 111:3316-3326.
4. Devereux R.B., Brown W.T., Kramer-Fox R., Sachs B.S. Inheritance of mitral valve prolapse: effect of age and sex on gene expression. Ann Intern Med 1982, 97:826-832.
5. Bonita R.E., Cohen I.S., Berko B.A. Valvular heart disease in osteogenesis imperfecta. Echocardiography 2010, 27:69-73.
6. Hinton R.B., Yutzey K.E. Heart valve structure and function in development and disease. Annu Rev Physiol 2011, 73:29-46.
7. Wirrig E.E., Hinton R.B., Yutzey K.E. Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. J Mol Cell Cardiol 2011, 50:561-569.
8. Aikawa E., Nahrendorf M., Sosnovik D., Lok V.M., Jaffer F.A., Aikawa M., et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 2007, 115:377-386.
9. Miller J.D., Weiss R.M., Heistad D.D. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res 2011, 108:1392-1412.
10. Garg V., Muth A.N., Ransom J.F., Schluterman M.K., Barnes R., King I.N., et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437:270-274.
11. Nigam V., Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol 2009, 47:828-834.
12. Nus M., MacGrogan D., Martinez-Poveda B., Benito Y., Casanova J.C., Fernandez-Aviles F., et al. Diet-induced aortic valve disease in mice haploinsufficient for the Notch pathway effector RBPJK/CSL. Arterioscler Thromb Vasc Biol 2011, 31:1580-1588.
13. Lincoln J., Kist R., Scherer G., Yutzey K.E. Sox9 is required for precursor cell expansion and extracellular matrix gene expression. Dev Biol 2007, 302:376-388.
14. Peacock J.D., Levay A.K., Gillaspie D.B., Tao G., Lincoln J. Reduced Sox9 function promotes heart valve calcification phenotypes in vivo. Circ Res 2010, 106:712-719.
15. Thubrikar M.J., Jaffar A., Nolan S.P. Patterns of calcific deposits in operatively excised stenotic of purely regurgitant aortic valves and their relation to mechanical stress. Am J Cardiol 1986, 58:304-308.
16. Chipman S.D., Sweet H.O., McBride D.J., Davisson M.T., Marks S.C., Shuldiner A.R., et al. Defective proa2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad Sci U S A 1993, 90:1701-1705.
17. Malfait F., Symoens S., Coucke P., Nunes L., De Almeida S., De Paepe A. Total absence of the alpha2(I) chain of collagen type I causes a rare form of Ehlers-Danlos syndrome with hypermobility and propensity of cardiac valvular problems. J Med Genet 2006, 42:e36.
18. Weis S.M., Emery J.L., Becker K.D., McBride D.J., Omens J.H., McCulloch A.D. Myocardial mechanics and collagen structure in the osteogenesis imperfecta murine (oim). Circ Res 2000, 87:663-669.
19. Kruzynska-Frejtag A., Machnicki M., Rogers R., Markwald R.R., Conway S.J. Periostin (an osteoblast-specific factor) is expressed within the embryonic mouse heart during valve formation. Mech Dev 2001, 103:183-188.
20. Snider P., Hinton R.B., Moreno-Rodriguez R., Wang J., Rogers R., Lindsley A., et al. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res 2008, 102:752-760.
21. Norris R.A., Moreno-Rodriguez R.A., Sugi Y., Hoffman S., Amos J., Hart M.M., et al. Periostin regulates atrioventricular valve maturation. Dev Biol 2008, 316:200-213.
22. Tkatchenko T.V., Moreno-Rodriguez R.A., Conway S.J., Molkentin J.D., Markwald R.R., Tkatchenko A.V. Lack of periostin leads to suppression of Notch1 signaling in calcific aortic valve disease. Physiol Genomics 2009, 39:160-168.
23. Hakuno D., Kimura N., Yoshioka M., Mukai M., Kimura T., Okada Y., et al. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. J Clin Invest 2010, 120:2292-2306.
24. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
25. Takeshita K., Fujimori T., Kurotaki Y., Honjo T., Tsujikawa H., Yasui K., et al. Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation 2004, 109:1776-1782.
26. Hu M.C., Shi M., Zhang J., Quinones H., Griffith C., Kuro-o M., et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011, 22:124-136.
27. Saban J., King D. PCR genotyping of oim mutant mice. Biotechniques 1996, 21:190.
28. Oka T., Kaiser R.A., Melendez J., Hambleton M., Sargent M.A., Lorts A., et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res 2007, 101:313-321.
29. Nakatani T., Sarraj B., Ohnishi M., Densmore M.J., Taguchi T., Goetz R., et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J 2009, 23:433-441.
30. Piedrahita J.A., Zhang S.H., Hagaman J.R., Oliver P.M., Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A 1992, 89:4471-4475.
31. Tanaka K., Sata M., Fukuda D., Suematsu Y., Motomura N., Takamoto S., et al. Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol 2005, 46:134-141.
32. Lincoln J., Alfieri C.M., Yutzey K.E. Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos. Dev Dyn 2004, 230:239-250.
33. Hinton R.B., Lincoln J., Deutsch G.H., Osinska H., Manning P.B., Benson D.W., et al. Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res 2006, 98:1431-1438.
34. Hinton R.B., Alfieri C.M., Witt S.A., Glascock B.J., Khoury P.R., Benson D.W., et al. Mouse heart valve structure and function: echocardiographic and morphometric analyses from the fetus through the aged adult. Am J Physiol Heart Circ Physiol 2008, 294:H2480-H2488.
35. Wirrig E.E., Snarr B.S., Chintalapudi M.R., O'Neal J.L., Phelps A.L., Barth J.L., et al. Cartilage link protein (Crtl1), an extracellular matrix component playing an important role in heart development. Dev Biol 2007, 310:291-303.
36. Chakraborty S., Cheek J., Sakthivel B., Aronow B.J., Yutzey K.E. Shared gene expression profiles in developing heart valves and osteoblasts. Physiol Genomics 2008, 35:75-85.
37. Chakraborty S., Wirrig E.E., Hinton R.B., Merrill W.H., Spicer D.B., Yutzey K.E. Twist1 promotes heart valve cell proliferation and extracellular matrix gene expression during development in vivo and is expressed in human diseased aortic valves. Dev Biol 2010, 347:167-179.
38. zur Nieden N.I., Kempka G., Ahr H.J. In vitro differentiation of embryonic stem cells into mineralized osteoblasts. Differentiation 2003, 71:18-27.
39. Norris R.A., Damon B., Mironov V., Kasyanov V., Ramamurthi A., Moreno-Rodriguez R., et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem 2007, 101:695-711.
40. Aikawa E., Whittaker P., Farber M., Mendelson K., Padera R.F., Aikawa M., et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult. Circulation 2006, 113:1344-1352.
41. Shelton E.L., Yutzey K.E. Twist1 function in endocardial cell proliferation, migration, and differentiation during heart valve development. Dev Biol 2008, 317:282-295.
42. Rabkin E., Aikawa M., Stone J.R., Fukumoto Y., Libby P., Schoen F.J. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001, 104:2525-2532.
43. Gupta V., Barzilla J.E., Mendez J.S., Stephens E.H., Lee E.L., Collard C.D., et al. Abundance and localization of proteoglycans and hyaluronan within normal and myxomatous mitral valves. Cardiovasc Pathol 2009, 18:191-197.
44. Bi W., Deng J.M., Zhang Z., Behringer R.R., de Crombrugghe B. Sox9 is required for cartilage formation. Nat Genet 1999, 22:85-89.
45. Lincoln J., Lange A.W., Yutzey K.E. Hearts and bones: Shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev Biol 2006, 294:292-302.
46. Otto C.M. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol 2006, 47:2141-2151.
47. Sider K.L., Blaser M.C., Simmons C.A. Animal models of calcific aortic valve disease. Int J Inflamm 2011, 2011:364310.
48. Maher E.R., Young G., Smyth-Walsh B., Pugh S., Curtis J.R. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 1987, 2:875-877.
49. Visconti R.P., Ebihara Y., LaRue A.C., Fleming P.A., McQuinn T.C., Masuya M., et al. An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circ Res 2006, 98:690-696.
50. Paruchuri S., Yang J.H., Aikawa E., Melero-Martin J.M., Khan Z.A., Loukogeorgakis S., et al. Human pulmonary valve progenitor cells exhibit endothelial/mesenchymal plasticity in response to vascular endothelial growth factor-A and transforming growth factor-beta2. Circ Res 2006, 99:861-869.
51. Mohler E.R., Gannon F., Reynolds C., Zimmerman R., Keane M.G., Kaplan F.S. Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
52. Miller J.D., Weiss R.M., Serrano K.M., Casteneda L.E., Brooks R.M., Zimmerman K., et al. Evidence for active regulation of pro-osteogenic signaling in advanced aortic valve disease. Arterioscler Thromb Vasc Biol 2010, 30:2482-2486.
53. Li C., Xu S., Gotlieb A.I. The response to valve injury. A paradigm to understand the pathogenesis of heart valve disease. Cardiovasc Pathol 2011, 20:183-190.
54. Weiss R.M., Ohashi M., Miller J.D., Young S.G., Heistad D.D. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 2006, 114:2065-2069.
55. Piers L.H., Touw H.R.W., Gansevoort R., Franssen C.F.M., Oudkerk M., Zijlstra F., et al. Relation of aortic valve and coronary artery calcium in patients with chronic kidney disease to the stage and etiology of the renal disease. Am J Cardiol 2009, 103:1473-1477.
56. Bonow R.O., Carabello B.A., Kanu C., de Leon A.C., Faxon D.P., Freed M.D., et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006, 114:e84-e231.
57. Rajamannan N.M., Subramaniam M., Stock S.R., Stone N.J., Springett M., Ignatiev K.I., et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005, 91:806-810.
58. Miller J.D., Weiss R.M., Serrano K.M., Brooks R.M., Berry C.J., Zimmerman K., et al. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 2009, 119:2693-2701.
59. Rossebo A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.